MARKET

SYNH

SYNH

SYNEOS HEALTH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

93.46
-0.88
-0.93%
Closed 16:06 09/20 EDT
OPEN
93.09
PREV CLOSE
94.34
HIGH
94.37
LOW
92.62
VOLUME
385.45K
TURNOVER
--
52 WEEK HIGH
97.48
52 WEEK LOW
50.27
MARKET CAP
9.67B
P/E (TTM)
41.75
1D
5D
1M
3M
1Y
5Y
Is Syneos Health, Inc. (NASDAQ:SYNH) Potentially Undervalued?
Syneos Health, Inc. ( NASDAQ:SYNH ), is not the largest company out there, but it saw a decent share price growth in...
Simply Wall St. · 19h ago
NOVN: Syneos Selected as Commercialization Partner
By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT September Update On September 9, 2021, Novan (NASDAQ:NOVN) hosted a corporate update conference call and webcast. The call was led by Novan President and CEO, Paula Brown Stafford, wh...
Zacks Small Cap Research · 23h ago
BlackRock Series Fund II, Inc. Buys SM Energy Co, Syneos Health Inc, Diamondback Energy Inc, ...
GuruFocus News · 4d ago
Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm
Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.
Zacks · 4d ago
BlackRock Income Fund Buys VanEck J.P. Morgan EM Local Currency Bond ETF, Telenet Group Holding ...
GuruFocus News · 5d ago
BlackRock Funds V Buys Syneos Health Inc, SM Energy Co, Diamondback Energy Inc, Sells Bausch ...
GuruFocus News · 5d ago
BRIEF-Syneos Health Acquires Studykik
reuters.com · 6d ago
Syneos Health Acquires StudyKIK
Acquisition Offers Sites and Sponsors Access to Technology-Enabled, Insight-Powered Solutions, Accelerating Clinical Trial Recruitment, Retention and DiversityMORRISVILLE, N.C., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only full...
GlobeNewswire · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYNH. Analyze the recent business situations of SYNEOS HEALTH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYNH stock price target is 102.00 with a high estimate of 115.00 and a low estimate of 93.00.
EPS
Institutional Holdings
Institutions: 456
Institutional Holdings: 144.97M
% Owned: 140.09%
Shares Outstanding: 103.48M
TypeInstitutionsShares
Increased
169
16.09M
New
60
4.53M
Decreased
66
3.18M
Sold Out
34
11.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Independent Director
John Dineen
Chief Executive Officer/Director
Alistair Macdonald
Chief Financial Officer
Jason Meggs
Corporate Executive
Paul Colvin
Corporate Executive
Michelle Keefe
Chief Human Resource Officer
Lisa Van Capelle
Senior Vice President - Finance/Chief Accounting Officer
Donna Kralowetz
General Counsel/Secretary
Jonathan Olefson
Independent Director
Todd Abbrecht
Independent Director
Thomas Allen
Independent Director
Bernadette Connaughton
Independent Director
Linda Harty
Independent Director
William Klitgaard
Independent Director
Kenneth Meyers
Independent Director
Matthew Monaghan
Independent Director
David Wilkes
No Data
  • All
  • Financials
  • Insiders
More
About SYNH
Syneos Health, Inc. is a biopharmaceutical solutions company. The Company provides a range of clinical and commercial services to customers in the pharmaceutical, biotechnology, and healthcare industries. It offers both stand-alone and integrated biopharmaceutical product development solutions ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. The Company operates through two business segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers a range of services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings such as clinical monitoring, investigator recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including deployment solutions, communication solutions, and consulting services.

Webull offers kinds of Syneos Health Inc stock information, including NASDAQ:SYNH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYNH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYNH stock methods without spending real money on the virtual paper trading platform.